DENTSPLY SIRONA Crecimiento futuro
Future controles de criterios 3/6
DENTSPLY SIRONA is forecast to grow earnings and revenue by 48.3% and 3.1% per annum respectively. EPS is expected to grow by 50.4% per annum. Return on equity is forecast to be 17% in 3 years.
Información clave
48.3%
Tasa de crecimiento de los beneficios
50.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 17.4% |
| Tasa de crecimiento de los ingresos | 3.1% |
| Rentabilidad financiera futura | 17.0% |
| Cobertura de analistas | Good |
| Última actualización | 25 Oct 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
DENTSPLY SIRONA (NASDAQ:XRAY) Hasn't Managed To Accelerate Its Returns
Oct 13
DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Is It Time To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Sep 05Is There An Opportunity With DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) 21% Undervaluation?
Aug 18Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Have Hit The Brakes
Jul 11A Tough Macro Environment Makes Dentsply Sirona's Turnaround Even Harder
Jul 02Insufficient Growth At DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Hampers Share Price
Jun 11We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
May 24Dentsply Sirona: I'm Buying The Pullback In This Medtech Leader
Apr 24Are Investors Undervaluing DENTSPLY SIRONA Inc. (NASDAQ:XRAY) By 47%?
Apr 22There's No Escaping DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Muted Revenues
Mar 10Here's Why DENTSPLY SIRONA (NASDAQ:XRAY) Has A Meaningful Debt Burden
Feb 16DENTSPLY SIRONA (NASDAQ:XRAY) Has More To Do To Multiply In Value Going Forward
Jan 29DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Shares Could Be 28% Below Their Intrinsic Value Estimate
Jan 11Is It Too Late To Consider Buying DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Nov 25These 4 Measures Indicate That DENTSPLY SIRONA (NASDAQ:XRAY) Is Using Debt Extensively
Nov 06Returns On Capital At DENTSPLY SIRONA (NASDAQ:XRAY) Paint A Concerning Picture
Oct 15An Intrinsic Calculation For DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Suggests It's 46% Undervalued
Sep 18DENTSPLY SIRONA (NASDAQ:XRAY) Has A Pretty Healthy Balance Sheet
Jul 31The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Jul 09A Look At The Fair Value Of DENTSPLY SIRONA Inc. (NASDAQ:XRAY)
Jun 20When Should You Buy DENTSPLY SIRONA Inc. (NASDAQ:XRAY)?
Jun 02Investors Don't See Light At End Of DENTSPLY SIRONA Inc.'s (NASDAQ:XRAY) Tunnel
May 15The Returns At DENTSPLY SIRONA (NASDAQ:XRAY) Aren't Growing
Apr 05Is DENTSPLY SIRONA (NASDAQ:XRAY) Using Too Much Debt?
Mar 07We Think DENTSPLY SIRONA (NASDAQ:XRAY) Can Stay On Top Of Its Debt
Nov 09Dentsply Sirona names Glenn Coleman as new CFO
Sep 22Dentsply Sirona hires Simon Campion as president, CEO
Aug 25Dentsply Sirona receives noncompliance notice from Nasdaq
Aug 16Dentsply Sirona: Weakening Fundamentals Outweigh 'Defensives' Argument
Jul 18Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 4,147 | 311 | 345 | N/A | 11 |
| 12/31/2025 | 3,994 | 246 | 294 | 402 | 14 |
| 12/31/2024 | 3,880 | 125 | 313 | 365 | 15 |
| 6/30/2024 | 3,896 | -185 | 364 | 527 | N/A |
| 3/31/2024 | 3,940 | -95 | 279 | 423 | N/A |
| 12/31/2023 | 3,965 | -132 | 228 | 377 | N/A |
| 9/30/2023 | 3,936 | -214 | 218 | 359 | N/A |
| 6/30/2023 | 3,936 | -1,025 | 198 | 334 | N/A |
| 3/31/2023 | 3,931 | -1,038 | 259 | 403 | N/A |
| 12/31/2022 | 3,922 | -950 | 368 | 517 | N/A |
| 9/30/2022 | 4,042 | -816 | 439 | 597 | N/A |
| 6/30/2022 | 4,135 | 345 | 499 | 660 | N/A |
| 3/31/2022 | 4,174 | 368 | 545 | 701 | N/A |
| 12/31/2021 | 4,231 | 411 | 515 | 657 | N/A |
| 9/30/2021 | 4,207 | 401 | 584 | 712 | N/A |
| 6/30/2021 | 4,062 | 370 | 634 | 748 | N/A |
| 3/31/2021 | 3,491 | 179 | 617 | 708 | N/A |
| 12/31/2020 | 3,339 | -73 | 562 | 649 | N/A |
| 9/30/2020 | 3,371 | -80 | 575 | 672 | N/A |
| 6/30/2020 | 3,438 | -48 | 524 | 623 | N/A |
| 3/31/2020 | 3,957 | 84 | 479 | 594 | N/A |
| 12/31/2019 | 4,022 | 256 | 516 | 639 | N/A |
| 9/30/2019 | 3,977 | 162 | 397 | 536 | N/A |
| 6/30/2019 | 3,944 | 105 | 337 | 502 | N/A |
| 3/31/2019 | 3,976 | -1,053 | 291 | 474 | N/A |
| 12/31/2018 | 3,986 | -1,011 | 312 | 500 | N/A |
| 9/30/2018 | 4,018 | -1,663 | 345 | 527 | N/A |
| 6/30/2018 | 4,098 | -1,601 | 398 | 565 | N/A |
| 3/31/2018 | 4,049 | -1,529 | N/A | 575 | N/A |
| 12/31/2017 | 3,993 | -1,550 | N/A | 602 | N/A |
| 9/30/2017 | 3,899 | -793 | N/A | 595 | N/A |
| 6/30/2017 | 3,844 | -791 | N/A | 584 | N/A |
| 3/31/2017 | 3,873 | 365 | N/A | 645 | N/A |
| 12/31/2016 | 3,745 | 430 | N/A | 563 | N/A |
| 9/30/2016 | 3,420 | 382 | N/A | 467 | N/A |
| 6/30/2016 | 3,115 | 374 | N/A | 474 | N/A |
| 3/31/2016 | 2,791 | 312 | N/A | 433 | N/A |
| 12/31/2015 | 2,674 | 251 | N/A | 497 | N/A |
| 9/30/2015 | 2,722 | 277 | N/A | 564 | N/A |
| 6/30/2015 | 2,782 | 268 | N/A | 551 | N/A |
| 3/31/2015 | 2,849 | 314 | N/A | 561 | N/A |
| 12/31/2014 | 2,923 | 323 | N/A | 560 | N/A |
| 9/30/2014 | 2,957 | 313 | N/A | 527 | N/A |
| 6/30/2014 | 2,953 | 317 | N/A | 506 | N/A |
| 3/31/2014 | 2,949 | 314 | N/A | 446 | N/A |
| 12/31/2013 | 2,951 | 313 | N/A | 418 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: XRAY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Beneficios vs. Mercado: XRAY is forecast to become profitable over the next 3 years, which is considered above average market growth.
Beneficios de alto crecimiento: XRAY is expected to become profitable in the next 3 years.
Ingresos vs. Mercado: XRAY's revenue (3.1% per year) is forecast to grow slower than the US market (8.9% per year).
Ingresos de alto crecimiento: XRAY's revenue (3.1% per year) is forecast to grow slower than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: XRAY's Return on Equity is forecast to be low in 3 years time (17%).